These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

74 related items for PubMed ID: 12536552

  • 1. [Effects of angiotension II receptor antagonist on the level ET and NO in the patients with renal hypertension and protection of renal function].
    Zhou QL, Deng SL, Yang JH.
    Hunan Yi Ke Da Xue Xue Bao; 2001 Dec 28; 26(6):583-4. PubMed ID: 12536552
    [No Abstract] [Full Text] [Related]

  • 2. [Study on the relationship between plasma endothelin nitric oxide concentration and renal hypertension and renal function].
    Zhou Q, Sun M, Zhou H.
    Hunan Yi Ke Da Xue Xue Bao; 1999 Dec 28; 24(4):381-3. PubMed ID: 12080656
    [Abstract] [Full Text] [Related]

  • 3. [The protection of renal function in the ACEI treatment of renal hypertension].
    Zhou QL, Yang JH, Chen LP.
    Hunan Yi Ke Da Xue Xue Bao; 2000 Aug 28; 25(4):385-7. PubMed ID: 12206011
    [Abstract] [Full Text] [Related]

  • 4. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T, Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.
    Clin Exp Nephrol; 2003 Sep 28; 7(3):221-30. PubMed ID: 14586719
    [Abstract] [Full Text] [Related]

  • 5. [Protective effect of angiotensin II receptor blockage on rats with experimental diabetes nephropathy in early stage].
    Yang L, Fan J, Mi X, Liu X, Xu G.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Apr 28; 34(2):317-9. PubMed ID: 12947726
    [Abstract] [Full Text] [Related]

  • 6. Anti-proteinuric effect of angiotension II receptor antagonist losartan in cases with glomerular lesions.
    Usta M, Dilek K, Yavuz M, Ersoy A, Güllülü M, Yurtkuran M.
    Clin Nephrol; 2001 Mar 28; 55(3):260-2. PubMed ID: 11316250
    [No Abstract] [Full Text] [Related]

  • 7. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension.
    Bayorh MA, Ganafa AA, Eatman D, Walton M, Feuerstein GZ.
    Am J Hypertens; 2005 Nov 28; 18(11):1496-502. PubMed ID: 16280288
    [Abstract] [Full Text] [Related]

  • 8. Long-term effects of losartan on proteinuria and renal function in patients with renal amyloidosis.
    Dilek K, Usta M, Ersoy A, Ozdemir B, Yavuz M, Güllülü M, Yurtkuran M.
    Scand J Urol Nephrol; 2002 Nov 28; 36(6):443-6. PubMed ID: 12623509
    [Abstract] [Full Text] [Related]

  • 9. Time-dependent expression of renal vaso-regulatory molecules in LPS-induced endotoxemia in rat.
    Yamaguchi N, Jesmin S, Zaedi S, Shimojo N, Maeda S, Gando S, Koyama A, Miyauchi T.
    Peptides; 2006 Sep 28; 27(9):2258-70. PubMed ID: 16725227
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.
    Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K.
    Hepatology; 2004 Nov 28; 40(5):1222-5. PubMed ID: 15382153
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Endothelin-1 and nitric oxide in patients on chronic hemodialysis.
    Tomić M, Galesić K, Markota I.
    Ren Fail; 2008 Nov 28; 30(9):836-42. PubMed ID: 18925520
    [Abstract] [Full Text] [Related]

  • 13. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B.
    Curr Med Res Opin; 2004 Mar 28; 20(3):333-40. PubMed ID: 15025842
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H, Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H.
    Ther Apher Dial; 2004 Aug 28; 8(4):320-7. PubMed ID: 15274684
    [Abstract] [Full Text] [Related]

  • 15. [Effect of treatment with labetalol on renal function in arterial hypertension secondary to parenchymal nephropathy and in essential arterial hypertension].
    Palla R, Bionda A, Carmassi F, Giusti R, Marchitiello M.
    Recenti Prog Med; 1980 Nov 28; 69(5):551-5. PubMed ID: 7465989
    [No Abstract] [Full Text] [Related]

  • 16. The role of endothelin-1 and nitric oxide in the pathogenesis of hypertension in diabetic patients.
    Tomić M, Galesić K, Morović-Vergles J, Romić Z, Mikulić I.
    Coll Antropol; 2008 Mar 28; 32(1):93-8. PubMed ID: 18496905
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 28; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Arterial hypertension in chronic glomerulonephritis: detectability and treatment efficacy].
    Kutyrina IM, Martynov SA, Shvetsov MIu, Lifshits NL, Miroshnichenko NG, Golitsina EP, Varshavskiĭ VA.
    Ter Arkh; 2004 Oct 28; 76(9):10-5. PubMed ID: 15532369
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.